Theracryf Plc logo

Theracryf Plc(LSE) EVG

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-99%
5 Year-97%
1 Year-10%
1 Month+9%
N/A
Theracryf Plc last closing stock price
MetricPriceDate
Last closeGBX 0.192026-10-20
Theracryf Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+8.57%GBX 0.182026-10-13
1 month+8.57%GBX 0.182026-09-18
3 month-9.52%GBX 0.212026-07-22
Year to date-5%GBX 0.202025-12-31
1 year-9.52%GBX 0.212025-10-20
3 year-89.73%GBX 1.852023-10-20
5 year-96.78%GBX 5.902021-10-21
Since inception-99.48%GBX 0.352015-10-21

Theracryf Plc Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£838.00K

Net Income (TTM)

-£7.18M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

May 3, 2024

EVG News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Theracryf Plc

Evgen Pharma plc is a UK-based pharmaceutical company focused on developing innovative sulforaphane-based medications to combat various cancers and inflammatory conditions. Founded in 2014, the company utilizes its proprietary Sulforadex technology to stabilize sulforaphane, with its lead drug candidate, SFX-01, currently in clinical trials.

Products and Services
  • SFX-01: Lead drug candidate for metastatic breast cancer and glioblastoma
  • Preclinical investigations for haematological malignancies
  • Out-licensing services for proprietary technology
Growth Outlook
  • Ongoing Phase II trials for SFX-01 indicate potential market entry
  • Strong focus on expanding research into additional cancer types
  • Partnership opportunities may enhance development capabilities
Financial Highlights
  • Recent quarterly revenue of 396,000 GBP shows growth from previous periods
  • Cash reserves of 2,004,000 GBP as of March 2024 support ongoing operations
  • Operating expenses reflect significant investment in research and development
Evgen Pharma plc is positioned in the biotechnology sector, with a clear focus on addressing unmet medical needs through innovative therapies. The company's lead candidate, SFX-01, is undergoing critical clinical trials, which could pave the way for future revenue streams. The financial data indicates a commitment to research and development, essential for long-term growth. With a solid cash position, Evgen Pharma is well-equipped to navigate the challenges of clinical development and capitalize on potential market opportunities.
AI Generated • Oct 5, 2026

Industry

Biotechnology

Sector

Health Care

Employees

9

CEO

Huw Jones, PhD

Website

www.evgen.com

Headquarters

Nether Alderley, SK10 4TG, GB

EVG Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-93.92%

Return on Capital

-152.33%

Return on Assets

-73.35%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

£825.00K

Operating Income

-£8.67M

EBITDA

-£8.64M

Operating Cash Flow

-£7.03M

Capital Expenditure

-£1.00K

Free Cash Flow

-£7.03M

Cash & ST Invst.

£2.00M

Total Debt

£0.00

Theracryf Plc Performance Analysis

Theracryf Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31GBP 442,000N/A
20242024-03-31GBP 396,000-10.4%
20252025-03-31GBP 0N/A
20262026-03-31GBP 0N/A
Theracryf Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22022-09-30N/A
Q42023-03-31N/A
Q22023-09-30-10.4%
Q42024-03-31-100.0%
Theracryf Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31GBP -0.0148.5%
20242024-03-31GBP -0.01-22.4%
20252025-03-31GBP -0.00-68.4%
20262026-03-31GBP -0.00-55.6%
Theracryf Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22022-09-30-77.3%
Q42023-03-3111.5%
Q22023-09-3023.2%
Q42024-03-31-7.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2023YOY CHG

Revenue

£0.00

N/A

Gross Profit

£6.00K

+185.7%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

10

N/A

Net Income

-£1.68M

-39.1%

EBITDA

-£2.10M

-26.1%

Quarterly Fundamentals

Name
Q4 2023YOY CHG

Total Cash

£2.00M

-77.8%

Total Debt

£0.00

N/A

Accounts Receivable

£0.00

-100.0%

Inventory

£0.00

+100.0%

Long Term Debt

£0.00

N/A

Short Term Debt

£0.00

N/A

Return on Assets

-73.35%

N/A

Return on Invested Capital

-1.18%

N/A

Free Cash Flow

-£1.72M

-69.0%

Operating Cash Flow

-£1.72M

-68.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DEST.LDestiny Pharma plc
£0.03-25.00%
ONC.LOncimmune Holdings plc
£0.01-4.20%
CNSL.LCambridge Nutritional Sciences plc
£0.02-7.66%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$100.58+1.96%
CRWVCoreWeave
$62.77+2.70%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$45.73-1.93%
BRZEBraze
$45.44+51.27%

Questions About EVG

What is the current price of Theracryf Plc?

Theracryf Plc is trading at N/A per share.

What is the 52-week range for Theracryf Plc?

Over the past 52 weeks, Theracryf Plc has traded between N/A and N/A.

How much debt does Theracryf Plc have?

As of the most recent reporting period, Theracryf Plc reported total debt of £11.00K.

How much cash does Theracryf Plc have on hand?

Theracryf Plc reported £471.00K in cash and cash equivalents in its most recent financial results.

What is Theracryf Plc’s dividend yield?

Theracryf Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services